Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: An antigen-binding molecule comprising a first antigen-binding moiety that is capable of binding to CD3 and CD137 (4-1BB), but does not bind to CD3 and CD137 at the same time (i.e. dual-binding to CD3 and CD137 but not simultaneously); and a second antigen-binding moiety capable of binding to a molecule specifically expressed in a cancer tissue, specifically Glypican-3 (GPC3) is provided. Due to the dual binding to CD3 and CD137 but not simultaneously and with fine-tuned binding kinetics, and the binding to GPC3, the multispecific antigen-binding molecule express strong cytotoxic activity for cancer cells with reduced adverse effects. Further, by adapting antibody engineering technologies and a molecular format design (including charged mutations in the framework region and/or constant region, VH/VL exchanged, and Fc region selection), the multispecific antigen-binding molecule with favorable stability, manufacturability/producibility and structural homogeneity is provided.

Abstract: Multispecific antigen-binding molecule capable of binding to multiple different antigens, but do not non-specifically crosslink two or more immune cells such as T cells are provided. Methods for producing or enriching a preferred structural form of such multispecific antibody protein, and method for eliminating disulfide heterogeneity of such multispecific antibody proteins are provided. In addition, conformation-specific antibodies that specifically recognize the preferred form of multispecific antibody proteins, and use of the conformation-specific antibodies are provided.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.